Evidence Based Medicine presented by InpharmD™

A retrospective, cohort study conducted to determine the adjusted effect of body mass index (BMI), associated comorbidities, time, neighborhood-level sociodemographic factors, and other factors on risk for death due to COVID-19

A randomzied, double-blind, placebo-controlled, multicenter, phase 2, pilot trial conducted to determine whether inhaled SNG001 (recombinant interferon beta-1a) has the potential to reduce the severity of lower respiratory tract illness and accelerate recovery in patients diagnosed with COVID-19.

The purpose of this study was to evaluate the efficacy and safety of LY-CoV555 (bamlanivimab) in patients with recently diagnosed mild or moderate COVID-19 in the outpatient setting

What does the evidence says on the safety and immunogenicity of pfizer's potential vaccine - BNT162b2 - as compared to other candidates?

A cohort study examining levels of severity of depressive symptoms over time among individuals with high risk in the UK during the COVID-19 pandemic

A randomized, double-blind, placebo-controlled trial conducted to assess if early intervention with interleukin-6 receptor blockade might limit COVID-19 progression to hypoxemic respiratory failure or death, reduce the risk of clinical worsening, and decrease the duration of supplemental oxygen use.

A 25-year old male patient was infected on two separate occasions, with the second infection being symptomatically more severe than the first. Genomic analysis showed the two viral agents were genetically distinct.

The objective of this study was to evaluate the clinical efficacy and safety of remdesivir among hospitalized adults with laboratory-confirmed COVID-19.

The objective of the cohort study was to investigate the effect of serum testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 in SARS-CoV-2 infected male patients

The objective of this study was to use the Extracorporeal Life Support Organization (ELSO) Registry to report the epidemiology, treatment, outcomes, and hospital characteristics of patients receiving extracorporeal membrane oxygenation (ECMO)with a confirmed diagnosis of Corona Virus Disease 2019 (COVID-19).